AzTrials
AzTrials

Ligament; LaxityFLEXNCT05177549

Evaluation of Anterior Tibial Translation of the Knee in Healthy Women, at Two Times of the Menstrual Cycle, on Hormonal Contraceptives or Not (FLEX)

A study testing Bilateral knee examination with Lachmeter® in people with Ligament; Laxity, run by Centre Hospitalier Universitaire de Nice at 1 site in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Women's participation in sports at all levels has been increasing in recent decades. Many individual and team sports are at risk of anterior cruciate ligament (ACL) injury. This injury leads to a permanent or long-lasting interruption of sports practice and to significant medical and economic expenses. Read more about this study

Who is it for?
Ages 18 to 40 years, women onlyHealthy volunteers can take part
Conditions the study is for
Ligament; Laxity
What is being tested?
Bilateral knee examination with Lachmeter®
Could I receive a placebo?
No, everyone receives an active treatment
How many people
45 participants
Where
1 siteFrance
Study dates
8 Jun 2022to 4 Aug 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 40 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Woman between 18 and 40 years old
  • No history of surgery of the 2 lower limbs
  • No change in contraceptive method in the last 6 months
  • Signature of the informed consent
  • Affiliation to the social security system
  • To be at Day 14 of her menstrual cycle (+/-1 day) (the first day of the cycle (Day1) being considered as the first day of the menstrual period), except for those on micro-progestative contraception not regulated
Show all 13Show fewer
  • By inclusion group:
  • For women without hormonal contraception: No method of contraception Or a copper intrauterine device Regular cycles of 26 to 33 days
  • For women on estrogen-progestin contraception: Correct use of the estrogen-progestin pill according to the MA Or wearing a vaginal ring according to the MA protocol Or wearing a contraceptive skin patch according to the MA protocol Regular cycles of 26 to 33 days
  • For women on micro-progestin contraception : Continuous use of the micro-progestogen pill Or wearing a subcutaneous hormonal implant,
  • Exception: women on micro-progestin contraception who are not regulated:
  • They may have an irregular cycle or no cycle to be included
  • They can be included on any day if they have no cycle

Who cannot join

  • Pregnancy or breastfeeding in progress
  • Hormonal intrauterine device or injectable contraception
  • Menopause (defined as no menstruation for one year)
  • Surgery: tubal ligation, oophorectomy, adnexectomy, hysterectomy
  • History of microcrystalline or infectious pathology localized to the knee
  • History of systemic or localized inflammatory joint disease of the knee
Show all 14Show fewer
  • History of fracture, severe sprain or dislocation of the knee joint
  • History of osteoarticular or congenital diseases that may lead to laxity (Marfan syndrome, trisomy 21, Ehlers-Danlos syndrome...)
  • Sign of hyperlaxity evaluated by a Beighton score higher than 4 (see appendix)
  • BMI > 25
  • Daily alcohol consumption above the thresholds recommended by Public Health in France (more than 2 glasses per day)
  • Woman unable to understand the protocol
  • Intense or unusual physical exercise during the last 72 hours (e.g.: marathon, triathlon, competitive cycling race...)
  • Woman under guardianship, curatorship or deprived of liberty

Trial locations and contacts

1 site in 1 country.

France1 site
  • CHU de Nice

    Nice, 06300

Other trials in France

About this study

Women's participation in sports at all levels has been increasing in recent decades. Many individual and team sports are at risk of anterior cruciate ligament (ACL) injury. This injury leads to a permanent or long-lasting interruption of sports practice and to significant medical and economic expenses. Women are recognized as being more at risk of anterior cruciate ligament injury with a risk 6 times higher than men. Hyperlaxity is a risk factor for anterior cruciate ligament injury, but the pathophysiological bases are little studied. Hormonal impregnation and certain periods of the menstrual cycle (ovulatory phase) are risk factors for anterior cruciate ligament injury. It therefore seems interesting to investigators to study the influence of hormonal impregnation on ligament laxity. To date no study has investigated such a relationship.

Being tested
Bilateral knee examination with Lachmeter®
Keywords
hormonal impregnation
Medical subject headings
Joint Instability

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Bilateral knee examination with Lachmeter®Other

    Bilateral knee examination with Lachmeter®. Examination repeated 3 times on each knee

Study groups in NCT05177549
Study groupRoleWhat they receive
on estrogen-progestin contraceptionExperimentalNot described
Receives: Other: Bilateral knee examination with Lachmeter®
under micro-progestational contraceptionExperimentalNot described
Receives: Other: Bilateral knee examination with Lachmeter®
without hormonal contraceptionExperimentalNot described
Receives: Other: Bilateral knee examination with Lachmeter®

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. anterior tibial translation of the knee

    The anterior tibial translation of the knee will be considered as representative of the anterior laxity of the knee of women under hormonal contraception via the Lachman test at 30° measured with a digital arthrometer type Lachmeter® (bilateral examination repeated 3 times on each knee).The degree of laxity will be evaluated thanks to the international classification IKDC:

    • Grade A 0 to 2 mm = normal
    • Grade B 3 to 5 mm = almost normal
    • Grade C 6 to 10 mm = abnormal
    • Grade D > 10 mm = severely abnormal

    Measured: Day1 (inclusion visit)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Jan 2022
  2. Study start8 Jun 2022
  3. Primary completion4 Aug 2023
  4. Study completion4 Aug 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
45 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05177549
Sponsor's protocol ID
19-AOI-01
Acronym
FLEX
Status last verified
May 2026
First submitted
16 Nov 2021
Last updated
26 May 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Bilateral knee examination with Lachmeter® in people with Ligament; Laxity, run by Centre Hospitalier Universitaire de Nice at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 13 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 26 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

anterior tibial translation of the knee (time frame: Day1 (inclusion visit)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 May 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in